Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.
暂无分享,去创建一个
Quentin Lecrevisse | Michaela Novakova | Ester Mejstrikova | Ondrej Hrusak | Alberto Orfao | Vincent H J van der Velden | Ludovic Lhermitte | Lukasz Sedek | Tomasz Szczepanski | Jan Trka | Monika Brüggemann | E. Mejstrikova | A. Órfão | J. V. van Dongen | V. V. D. van der Velden | J. te Marvelde | O. Hrusak | E. Froňková | J. Trka | E. Sonneveld | L. Lhermitte | T. Szczepański | L. Sędek | Q. Lecrevisse | Giuseppe Gaipa | M. Brüggemann | P. Theunissen | A. J. van der Sluijs-Gelling | G. Gaipa | M. Bartels | E. Sobral da Costa | M. Kotrová | M. Nováková | C. Buracchi | P. Bonaccorso | Elen Oliveira | G. Grigore | Prisca Theunissen | Alita J van der Sluijs-Gelling | Marius Bartels | Elaine Sobral da Costa | Michaela Kotrová | Edwin Sonneveld | Chiara Buracchi | Paola Bonaccorso | Elen Oliveira | Jeroen G Te Marvelde | Georgiana Emilia Grigore | Eva Froňková | Jacques J M van Dongen | E. Oliveira | Elaine Sobral da Costa
[1] A Orfao,et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes , 2012, Leukemia.
[2] C. E. Pedreira,et al. Generation of flow cytometry data files with a potentially infinite number of dimensions , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[3] A. Órfão,et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL , 1999, Leukemia.
[4] E. Mejstrikova,et al. Minimal Residual Disease-Based Risk Stratification in Chinese Childhood Acute Lymphoblastic Leukemia by Flow Cytometry and Plasma DNA Quantitative Polymerase Chain Reaction , 2013, PloS one.
[5] B. Schäfer,et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia , 2008, Leukemia.
[6] A. Órfão,et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. , 2001, Leukemia.
[7] Yong-mei Zhu,et al. Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia , 2013, Blood Cancer Journal.
[8] J. Dongen,et al. GENE REARRANGEMENTS ARE FREQUENT IN PRECURSOR-B-ACUTE LYMPHOBLASTIC LEUKEMIA BUT RARE IN NORMAL LYMPHOID CELLS , 2003 .
[9] T. Kalina,et al. Transfer of genomics information to flow cytometry: expression of CD27 and CD44 discriminates subtypes of acute lymphoblastic leukemia , 2005, Leukemia.
[10] J. Dongen,et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia , 2004, Leukemia.
[11] J. V. Dongen,et al. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis , 2002, Leukemia.
[12] Alberto Orfao,et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. , 2015, Blood.
[13] I. Bernstein,et al. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. , 1996, Blood.
[14] Brent L Wood,et al. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry , 2016, Cytometry. Part B, Clinical cytometry.
[15] Elaine Coustan-Smith,et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. , 2011, Blood.
[16] Maria Grazia Valsecchi,et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Mejstrikova,et al. The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL. , 2015, Blood.
[18] G. Basso,et al. Expression of CD 58 in normal , regenerating and leukemic bone marrow B cells : implications for the detection of minimal residual disease in acute lymphocytic leukemia , 2003 .
[19] B. Paiva,et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting , 2016, Cytometry. Part B, Clinical cytometry.
[20] E. Mejstrikova,et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL , 2008, Bone Marrow Transplantation.
[21] J. V. van Dongen,et al. Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia : characteristics and applicability for the detection of minimal residual disease , 2006 .
[22] Maria Grazia Valsecchi,et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia , 2012, Haematologica.
[23] D. Campana,et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. , 2010, Blood.
[24] A J van der Sluijs-Gelling,et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2013, Leukemia.
[25] M. Loh,et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. , 2015, Blood.
[26] J. Dongen,et al. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. , 2009 .
[27] C. Mosse,et al. B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model. , 2015, American journal of clinical pathology.
[28] M. D. Boer,et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement , 2007, Leukemia.
[29] C. V. D. Schoot,et al. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR , 2002, Leukemia.
[30] T. Kalina,et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols , 2012, Leukemia.
[31] Barbara Buldini,et al. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia , 2015, Haematologica.
[32] R. Pieters,et al. Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood , 2014, Haematologica.
[33] Li Gao,et al. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia , 2016, Leukemia & lymphoma.
[34] Y. Hayashi,et al. Significance of CD66c expression in childhood acute lymphoblastic leukemia. , 2014, Leukemia research.
[35] J. V. van Dongen,et al. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. , 2009, Methods in molecular biology.
[36] J. Dongen,et al. Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring , 2008, Leukemia.
[37] A. Porwit,et al. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi‐centre study comparing real‐time polymerase chain reaction and multicolour flow cytometry , 2011, British journal of haematology.
[38] V. V. D. van der Velden,et al. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age‐related changes and disease‐induced shifts , 2004, Cytometry. Part B, Clinical cytometry.
[39] Marek Omelka,et al. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry , 2010, Pediatric blood & cancer.
[40] R. Stallings,et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time‐points reveals high levels of concordance between molecular and immunophenotypic approaches , 2009, British journal of haematology.
[41] J. Cayuela,et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.
[42] T. Kalina,et al. Myeloid antigens in childhood lymphoblastic leukemia:clinical data point to regulation of CD66c distinct from other myeloid antigens , 2005, BMC Cancer.
[43] Michael N Dworzak,et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.
[44] P. Rohrlich,et al. CD304 is preferentially expressed on a subset of B‐lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[45] B. Wood,et al. A novel flow cytometric assay for detection of residual disease in patients with B‐lymphoblastic leukemia/lymphoma post anti‐CD19 therapy , 2018, Cytometry. Part B, Clinical cytometry.
[46] E. Blennow,et al. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia , 2009, Haematologica.
[47] E S Costa,et al. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B‐cell chronic lymphoproliferative disorders , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[48] E. Mejstrikova,et al. High expression of cytoskeletal protein drebrin in TEL/AML1pos B-cell precursor acute lymphoblastic leukemia identified by a novel monoclonal antibody. , 2011, Leukemia research.